%0 Journal Article
%T The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab
%A Diana Brixner
%A Douglas S. Burgoyne
%A Gary Oderda
%A Joseph Biskupiak
%A Steven G. Avey
%A Steven R. Feldman
%J Archive of "American Health & Drug Benefits".
%D 2019
%X Payers often consider cost-effectiveness studies for new drugs when making decisions on coverage, formulary position, and budgets; however, cost-effectiveness studies are often calculated using estimated pricing before a drug's launch. If the drug's price changes on or after launch, or if rebate programs are initiated, cost-effectiveness studies need to be updated to prevent payers from making decisions using inaccurate value assumptions, which can lead to unexpected financial impacts and potentially delay patient access to drugs
%K brodalumab
%K cost-effectiveness
%K drug pricing
%K immunomodulators
%K plaque psoriasis
%K treatment decision-making
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404800/